Wuhan YZY Biopharma Co., Ltd.

SEHK:2496 Stock Report

Market Cap: HK$750.2m

Wuhan YZY Biopharma Balance Sheet Health

Financial Health criteria checks 3/6

Wuhan YZY Biopharma has a total shareholder equity of CN¥49.6M and total debt of CN¥119.5M, which brings its debt-to-equity ratio to 241%. Its total assets and total liabilities are CN¥260.0M and CN¥210.4M respectively.

Key information

241.0%

Debt to equity ratio

CN¥119.50m

Debt

Interest coverage ration/a
CashCN¥161.85m
EquityCN¥49.59m
Total liabilitiesCN¥210.37m
Total assetsCN¥259.96m

Recent financial health updates

Recent updates

Is Wuhan YZY Biopharma (HKG:2496) Using Debt In A Risky Way?

Oct 02
Is Wuhan YZY Biopharma (HKG:2496) Using Debt In A Risky Way?

Financial Position Analysis

Short Term Liabilities: 2496's short term assets (CN¥210.9M) exceed its short term liabilities (CN¥170.1M).

Long Term Liabilities: 2496's short term assets (CN¥210.9M) exceed its long term liabilities (CN¥40.3M).


Debt to Equity History and Analysis

Debt Level: 2496 has more cash than its total debt.

Reducing Debt: Insufficient data to determine if 2496's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 2496 has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: 2496 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 16.3% each year


Discover healthy companies